Form 4: Pulmonx Director Dana G. Mead Jr. Receives RSU Grant

Pulmonx Corporation director Dana G. Mead Jr. was granted 40,000 restricted stock units as part of an equity compensation award.

Summary

• Director Dana G. Mead Jr. acquired 40,000 restricted stock units (RSUs) on June 5, 2026.
• The RSUs are payable solely in common stock of Pulmonx Corporation.
• The grant vests on the earlier of the one-year anniversary of the grant date or the date of the next annual stockholders' meeting.
• Following this transaction, the director's direct beneficial ownership increased to 139,714 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• The issuance of 40,000 RSUs results in potential future dilution for existing shareholders.

Risks

• Market volatility affecting the future value of the equity compensation.

Future Outlook

The RSUs are scheduled to vest on June 5, 2027, or at the next annual meeting of stockholders, whichever occurs first.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure long-term alignment with company performance in the medical device sector.

Comparison to Industry Standards

• The use of RSU grants for director compensation is consistent with standard practices for mid-cap medical technology companies.
• Vesting schedules tied to annual meetings are common industry practice for board members.

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of the 40,000 RSUs on or before June 5, 2027.

Key Dates

Keywords

Pulmonx, LUNG, Form 4, Insider Trading, Equity Compensation, Director Compensation